CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. - Wikidata - wikimedia - TriplyDB

CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase.

CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase.

http://www.wikidata.org/entity/Q42876261

about

Targeting the indoleamine 2,3-dioxygenase pathway in cancer Advances on Non-CD4 + Foxp3+ T Regulatory Cells: CD8+, Type 1, and Double Negative T Regulatory Cells in Organ Transplantation Trial watch: IDO inhibitors in cancer therapy Effector mechanisms of rejection Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells Central memory CD8+ T lymphocytes mediate lung allograft acceptance.Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection.Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells The effects of tolerance on allograft damage caused by the innate immune system The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma.Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells Indoleamine 2,3 dioxygenase and metabolic control of immune responses.Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance A higher risk of acute rejection of human kidney allografts can be predicted from the level of CD45RC expressed by the recipients' CD8 T cells.Immuno-regulatory function of indoleamine 2,3 dioxygenase through modulation of innate immune responses.IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival.Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases.IL-34 is a Treg-specific cytokine and mediates transplant tolerance.Intragraft CD11b(+) IDO(+) cells mediate cardiac allograft tolerance by ECDI-fixed donor splenocyte infusions Regulation of autoimmune arthritis by the pro-inflammatory cytokine interferon-gamma.Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege Transfer of tolerance to heart and kidney allografts in the rat model.Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice Do Natural T Regulatory Cells become Activated to Antigen Specific T Regulatory Cells in Transplantation and in Autoimmunity?Indoleamine 2,3-dioxygenase in transplantation.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Emerging concepts in CD8(+) T regulatory cells IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses.T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.Modalities and future prospects of gene therapy in heart transplantation.Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.Role of IDO in organ transplantation: promises and difficulties.Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target.T-cell receptor specificity of CD8(+) Tregs in allotransplantation.Making sense of regulatory T cell suppressive function.Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.

P2860

Q26775471-5196671E-9930-4290-B166-B93A69CFDB68 Q26801808-13D29C17-C118-487A-80D2-0BC5E036AFCE Q27006866-D6D9FCC8-BC3A-4814-A824-FB206306B025 Q27027082-42C14522-7700-4C3D-B05C-B550491318B3 Q27311751-BBBECB79-1A02-4C0C-899F-59392AAF6309 Q30573064-96FB0F07-78E1-49FD-95A8-28D7E4189D82 Q33622404-6F72AF4E-22A9-4F25-95D3-AAA172B80F0E Q33685910-E5300582-7C18-4CE0-9DB0-5A23023D32BB Q33702231-4F445E82-149B-4F5B-BC0F-10703DF423B3 Q33757956-9C4C2E13-2AC3-4968-964E-BEC4BA810730 Q33929529-C68861A2-6038-42B5-A694-672385B553E6 Q34110557-4969D74B-35A0-4819-8E0E-E99A880ECB19 Q34308495-F8F81988-F105-4F9B-AD5F-2138CD594066 Q34333949-59DD50F2-1B5C-4870-A8A8-112425D4C5F1 Q34512092-686E0441-7AA2-489D-B3F2-14903ADF14ED Q34874489-C7B3C05F-BBCC-4193-9EBB-26011E4DB03A Q34936678-2B97C3D0-C602-4F91-BFC2-4164ECE89B16 Q35645172-1C92BBD1-2D3B-488E-902E-46B5F9031A40 Q35952614-803D33FC-0FA7-4BEA-A61F-47CB08F3E2BE Q36165650-3288AB3C-6A93-48BD-BD76-A5CE1FD71C4A Q36356879-34B0C64F-F45D-4C69-9863-8F39B11B97AA Q36662480-AEE8B39B-8438-4108-94E7-294D5EC3B95D Q36899012-2F5E7C45-C916-4823-8790-39D013AF3558 Q37028219-88F64D49-1F76-4183-90EE-D47B019314D0 Q37052040-3EA289AB-D585-453E-A370-4036F9F5BB06 Q37065735-0A44CC8F-A903-4FA5-BC36-CA64CF1A6F48 Q37067533-7BB61D14-1937-41F8-A4A0-DB3D145F1E7E Q37079141-92FCDF10-1705-4BEE-A71D-748C5ACF31C3 Q37136267-9417BCC7-8436-4868-A29F-774C09E5828A Q37195611-E8212BAD-1F2E-4F16-B366-837F09D8409E Q37334065-EEAF5306-B2D9-4AA5-A6A6-ADE6D62CF626 Q37352554-6D618B4D-E3A8-4F02-A258-731688947215 Q37422767-29433162-2F10-422F-ABEE-E2397E73AB13 Q37522460-30A42AF2-07C8-46ED-9938-0C87BFC44FA4 Q37528354-E46EF89D-CD9F-4F05-9D26-43770395BC89 Q37610449-CA438C58-724C-4576-AAF8-3778FB820B6B Q37766241-AE839EE8-FC6B-4AA0-AA37-AFE3D2CF0C4E Q37869491-3C29D488-641C-475A-9B14-B8C15B3BACDA Q37877042-CD319448-47F1-4E46-A1FA-4C2FBBDD5EB5 Q38047057-FFE32A1F-D9D5-4A06-A6D7-B85B77CAD0F2

P2860

CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase.

http://www.wikidata.org/entity/Q42876261

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

CD40Ig treatment results in al ...... d indoleamine 2,3-dioxygenase.

@en

CD40Ig treatment results in al ...... d indoleamine 2,3-dioxygenase.

@nl

type

label

CD40Ig treatment results in al ...... d indoleamine 2,3-dioxygenase.

@en

CD40Ig treatment results in al ...... d indoleamine 2,3-dioxygenase.

@nl

prefLabel

CD40Ig treatment results in al ...... d indoleamine 2,3-dioxygenase.

@en

CD40Ig treatment results in al ...... d indoleamine 2,3-dioxygenase.

@nl

P1433

Q42876261-5F46607E-F605-455F-828E-6F26E664D01A

P1476

Q42876261-CA333F8E-DC09-44B6-B679-CBACB4E99E6E

P2093

Q42876261-1ADF0219-53A0-44F9-A8FA-8F6B89988CED

Q42876261-68816BFB-30AA-40C7-B847-89509A509202

Q42876261-6F37755F-E84A-49EA-A762-CF0FAA2F90BD

Q42876261-8300A12B-244A-49E0-8D6E-24A7EDFF4FCF

Q42876261-A0D3497E-31AA-45A6-836F-6917B1C445E9

Q42876261-A31CA30C-D136-4337-AB2E-DE17FBDFAAC3

Q42876261-AB521224-DD68-4FDA-B9F7-903453B05AC9

Q42876261-C03ECC12-B2B4-4DD7-AEF7-8A3163C04103

Q42876261-D76D90A2-19FB-466F-A33D-3537FBFD7C84

Q42876261-E6A2CE23-3075-417B-9E93-E26960DCAE62

P2860

Q42876261-007DDA98-0381-4517-8BEE-5F62851E6376

Q42876261-0439132B-C891-416F-8EF4-3BB1718DAE2F

Q42876261-0640BD51-E915-4410-A3C3-B5442E6937F1

Q42876261-06BCEE74-242C-459B-8660-506E1861BB20

Q42876261-0C809E76-D35B-4C34-ADE7-8BD205944415

Q42876261-2244C38C-01AF-497E-9136-95561EF8A2D8

Q42876261-279621FF-1DCF-45AC-8651-A30B675F8416

Q42876261-2A93D757-0D00-40CD-A4A8-4D2CDC66412A

Q42876261-2B233291-4348-4407-A67A-5B9486487C36

Q42876261-2C30827F-A5A7-413C-AF92-E1134A1FCAD7

P304

Q42876261-4BD8316F-C6CF-42C0-8F9C-D6456976251B

P31

Q42876261-53EB5996-747C-4263-8904-86E617B1AE5F

P356

Q42876261-BA9C96D9-51A0-4C84-8AE3-5A1E6260B7C3

P407

Q42876261-683AFA86-AE3F-4134-A153-E8AC0B1934BD

P433

Q42876261-C2650A30-FE29-449A-82C6-15651349C8D8

P478

Q42876261-25FFCB58-61D7-46AC-A66B-04532ED0189B

P50

Q42876261-06E82BC7-1A96-40D3-A324-B014B7FDA04D

Q42876261-3098F896-D899-4159-8AEB-B5F386B61C0C

Q42876261-E420DAFE-A26F-4392-843E-C0579140E230

P577

Q42876261-064B444B-EB7E-4DB3-BFD3-4FA667A69C3B

P698

Q42876261-F3A954E0-03BF-4A15-8419-92E56BC15F4F

P932

Q42876261-4DB5A059-467A-47EF-9B37-0AA2F3B5D83D

P356

P1433

Journal of Clinical Investigation

P1476

CD40Ig treatment results in al ...... d indoleamine 2,3-dioxygenase.

@en

P2093

Abdelhadi Saoudi

http://www.w3.org/2001/XMLSchema#string

Brigitte Le Mauff

http://www.w3.org/2001/XMLSchema#string

Carole Guillonneau

http://www.w3.org/2001/XMLSchema#string

Caroline Hervé

http://www.w3.org/2001/XMLSchema#string

Claire Usal

http://www.w3.org/2001/XMLSchema#string

François-Xavier Hubert

http://www.w3.org/2001/XMLSchema#string

Ignacio Anegon

http://www.w3.org/2001/XMLSchema#string

Laurent Tesson

http://www.w3.org/2001/XMLSchema#string

Maria Cristina Cuturi

http://www.w3.org/2001/XMLSchema#string

Michèle Heslan

http://www.w3.org/2001/XMLSchema#string

P2860

Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4

Where CD4+CD25+ T reg cells impinge on autoimmune diabetes

Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase

Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor

IDO expression by dendritic cells: tolerance and tryptophan catabolism

The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1.

Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.

Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance.

Regulatory T cells in transplantation tolerance.

IDO and tolerance to tumors.

P304

1096-1106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI28801

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Elise Chiffoleau

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17404623

http://www.w3.org/2001/XMLSchema#string

P932

1839240

http://www.w3.org/2001/XMLSchema#string